Ameriprise’s Denali Therapeutics DNLI Stock Holding History

Ameriprise’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.13M	Sell	82,650 -6,884	-8%	-$141K	﹤0.01%	3046
2026 Q1	$1.72M	Sell	89,534 -90,687	-50%	-$1.8M	﹤0.01%	3025
2025 Q4	$2.98M	Buy	180,221 +80,660	+81%	+$1.36M	﹤0.01%	2785
2025 Q3	$1.45M	Sell	99,561 -2,472	-2%	-$35.5K	﹤0.01%	3177
2025 Q2	$1.43M	Buy	+102,033	New	+$1.44M	﹤0.01%	3113
2025 Q1	–	Sell	-16,743	Closed	-$341K	–	4053
2024 Q4	$341K	Buy	16,743 +9,343	+126%	+$239K	﹤0.01%	3675
2024 Q3	$216K	Buy	+7,400	New	+$183K	﹤0.01%	3728

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise's DNLI Position: Q2 2026 in Review

Ameriprise reduced its Denali Therapeutics (DNLI) stake by 7.7% in Q2 2026, selling an estimated $141K and leaving 82,650 shares worth $2.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3046.

Ameriprise first reported a position in DNLI in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.98M in Q4 2025. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Ameriprise held 82,650 shares of Denali Therapeutics worth $2.13M as of Q2 2026.
Ameriprise sold 6,884 Denali Therapeutics shares in Q2 2026, an estimated $141K.
Denali Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3046 holding.
Ameriprise first reported a position in Denali Therapeutics in Q3 2024 and has held it in 7 quarters since.
Ameriprise's Denali Therapeutics position peaked at $2.98M in Q4 2025.
294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.